The nervous system is capable of large, rapid alterations during repeated benzodiazepine dosing that can be measured as tolerance and dependence. Recent publications and preliminary data suggest that not all benzodiazepines produce the same patterns of tolerance or dependence. It is postulated that benzodiazepines of different structures can trigger various patterns of adaptive processes that could be detected as differing patterns of tolerance, dependence, and cross-tolerance. This will be studied by treating rats with a standard flurazepam treatment known to produce tolerance to benzodiazepine-induced motor impairment and anticonvulsant actions. These rats will be used to test for cross-tolerance using 8 benzodiazepines selected for their structural characteristics, or because of other data suggesting unusual patterns of tolerance or dependence. Based on previous work, tolerance will be sought for the anticonvulsant activity against the chemical convulsant pentylenetetrazol, and for locomotor impairment. These drugs, as well as flurazepam, will be compared in direct tolerance testing. Each will be given to rats for 4 weeks, then tolerance will be measured to the different drug actions. Physical dependence will also be examined, using the precipitated abstinence syndrome produced by a benzodiazepine antagonist, flumazepil (Ro15-1788). As patterns of tolerance, cross-tolerance and dependence emerge, various benzodiazepines will be chosen for further studies of cross- tolerance. The mechanisms that are the basis of tolerance and dependence remain unknown. Down-regulation of brain benzodiazepine receptors will be examined in rats treated with the various benzodiazepine, and data compared to previous results in flurazepam-treated tolerant rats. Receptors will be studied in brain homogenates, and also by quantitative receptor autoradiography, which was used to localize areas of downregulation in flurazepam-treated rats. To further examine possible mechanisms, an in vitro assay for receptor-coupled chloride ion flux was developed. This will be used to examine changes in the benzodiazepine receptor/GABA receptor/C1- channel complex, which is the machinery of GABA receptor- coupled inhibitory function, the site of acute benzodiazepine actions, and likely to be involved in chronic benzodiazepine actions. Using these various approaches, it should be possible to increase understanding of patterns of chronic benzodiazepine actions, and the mechanisms that are the basis of tolerance and dependence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA002194-12
Application #
3207174
Study Section
Special Emphasis Panel (SRCD (25))
Project Start
1985-02-01
Project End
1991-09-29
Budget Start
1990-02-01
Budget End
1991-09-29
Support Year
12
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of Toledo
Department
Type
Schools of Medicine
DUNS #
807418939
City
Toledo
State
OH
Country
United States
Zip Code
43614
Dong, Yu; Rosenberg, Howard C (2004) Brief seizure activity alters Ca2+/calmodulin dependent protein kinase II dephosphorylation and subcellular distribution in rat brain for several hours. Neurosci Lett 357:95-8
Dong, Yu; Rosenberg, Howard C (2004) Prolonged changes in Ca2+/calmodulin-dependent protein kinase II after a brief pentylenetetrazol seizure; potential role in kindling. Epilepsy Res 58:107-17
Li, M; Szabo, A; Rosenberg, H C (2001) Evaluation of native GABA(A) receptors containing an alpha 5 subunit. Eur J Pharmacol 413:63-72
Li, M; Szabo, A; Rosenberg, H C (2000) Down-regulation of benzodiazepine binding to alpha 5 subunit-containing gamma-aminobutyric Acid(A) receptors in tolerant rat brain indicates particular involvement of the hippocampal CA1 region. J Pharmacol Exp Ther 295:689-96
Walsh, L A; Li, M; Zhao, T J et al. (1999) Acute pentylenetetrazol injection reduces rat GABAA receptor mRNA levels and GABA stimulation of benzodiazepine binding with No effect on benzodiazepine binding site density. J Pharmacol Exp Ther 289:1626-33
Zhao, T J; Li, M; Chiu, T H et al. (1998) Decreased benzodiazepine binding with little effect on gamma-aminobutyric acid binding in rat brain after treatment with antisense oligodeoxynucleotide to the gamma-aminobutyric acidA receptor gamma-2 subunit. J Pharmacol Exp Ther 287:752-9
Zhao, T J; Rosenberg, H C; Chiu, T H (1996) Treatment with an antisense oligodeoxynucleotide to the GABAA receptor gamma 2 subunit increases convulsive threshold for beta-CCM, a benzodiazepine ""inverse agonist', in rats. Eur J Pharmacol 306:61-6
Tersigni, T J; Rosenberg, H C (1996) Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA. Brain Res 733:184-92
Rosenberg, H C (1995) Differential expression of benzodiazepine anticonvulsant cross-tolerance according to time following flurazepam or diazepam treatment. Pharmacol Biochem Behav 51:363-8
Wu, Y; Rosenberg, H C; Chiu, T H (1995) Rapid down-regulation of [3H]zolpidem binding to rat brain benzodiazepine receptors during flurazepam treatment. Eur J Pharmacol 278:125-32

Showing the most recent 10 out of 43 publications